Brokers Offer Predictions for STOK Q3 Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Equities research analysts at HC Wainwright issued their Q3 2025 earnings estimates for shares of Stoke Therapeutics in a research report issued on Wednesday, March 19th. HC Wainwright analyst A. Fein anticipates that the company will post earnings of ($0.55) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $47.00 target price on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share. HC Wainwright also issued estimates for Stoke Therapeutics’ Q4 2025 earnings at ($0.56) EPS, FY2025 earnings at ($2.18) EPS, FY2026 earnings at ($2.87) EPS, FY2027 earnings at ($2.06) EPS, FY2028 earnings at ($1.21) EPS and FY2029 earnings at $0.22 EPS.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Monday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.38. The firm had revenue of $22.61 million during the quarter, compared to analysts’ expectations of $4.20 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%.

Other equities research analysts have also recently issued reports about the stock. Chardan Capital reiterated a “buy” rating and issued a $24.00 price objective on shares of Stoke Therapeutics in a report on Wednesday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a report on Tuesday. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $23.00.

Stoke Therapeutics Trading Down 2.2 %

Shares of NASDAQ:STOK opened at $8.15 on Friday. The stock has a market capitalization of $431.68 million, a PE ratio of -3.88 and a beta of 0.99. Stoke Therapeutics has a 1 year low of $5.93 and a 1 year high of $17.58. The firm has a fifty day moving average price of $9.47 and a 200 day moving average price of $11.45.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. KLP Kapitalforvaltning AS acquired a new position in Stoke Therapeutics in the fourth quarter worth about $63,000. Teacher Retirement System of Texas acquired a new position in Stoke Therapeutics in the fourth quarter worth about $113,000. China Universal Asset Management Co. Ltd. acquired a new position in Stoke Therapeutics in the fourth quarter worth about $124,000. Tower Research Capital LLC TRC raised its position in Stoke Therapeutics by 70.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company’s stock worth $132,000 after purchasing an additional 4,918 shares in the last quarter. Finally, Invesco Ltd. acquired a new position in Stoke Therapeutics in the fourth quarter worth about $133,000.

Insider Buying and Selling at Stoke Therapeutics

In other news, insider Barry Ticho sold 3,884 shares of the company’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $33,674.28. Following the completion of the transaction, the insider now owns 63,962 shares of the company’s stock, valued at approximately $554,550.54. This represents a 5.72 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Edward M. Md Kaye sold 10,382 shares of the company’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $90,011.94. Following the transaction, the director now directly owns 148,253 shares of the company’s stock, valued at $1,285,353.51. This represents a 6.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 16,532 shares of company stock worth $143,332 over the last ninety days. Company insiders own 11.30% of the company’s stock.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.